These Analysts Cut Their Forecasts On Inspire Medical Systems Following Q3 Results

Core Insights - Inspire Medical Systems Inc reported better-than-expected third-quarter financial results, with earnings of 38 cents per share, surpassing the analyst consensus estimate of a loss of 19 cents per share [1] - The company also reported quarterly sales of $224.501 million, exceeding the analyst consensus estimate of $220.467 million [1] Financial Guidance - Inspire Medical Systems raised its FY2025 GAAP EPS guidance from a range of $0.40-$0.50 to $0.90-$1.00, while affirming sales guidance of $900 million-$910 million [2] Management Commentary - Tim Herbert, Chairman and CEO, highlighted the productive third quarter focused on the transition to the Inspire V system and presented clinical evidence of enhanced performance at recent industry meetings [3] Stock Performance - Following the earnings announcement, Inspire Medical shares increased by 17%, trading at $86.46 [3] Analyst Reactions - Wells Fargo upgraded Inspire Medical Systems from Equal-Weight to Overweight, lowering the price target from $101 to $90 [6] - JP Morgan maintained a Neutral rating, cutting the price target from $110 to $82 [6] - Truist Securities reiterated a Hold rating, reducing the price target from $90 to $84 [6] - RBC Capital maintained an Outperform rating, lowering the price target from $150 to $125 [6] - Piper Sandler reiterated an Overweight rating, reducing the price target from $150 to $135 [6]